Core Viewpoint - Beihai Kangcheng (01228) has seen a significant stock price increase, with a year-to-date rise exceeding 2000% as of the latest report, reflecting strong market interest and potential growth opportunities for the company [1] Group 1: Stock Performance - Beihai Kangcheng's stock price rose by over 19%, currently trading at 2.83 HKD, with a trading volume of 66.91 million HKD [1] - The cumulative increase in stock price for the year has surpassed 2000% [1] Group 2: Regulatory Developments - The National Healthcare Security Administration has established a new commercial insurance innovative drug directory, initiating the application process on July 11 [1] - Three of Beihai Kangcheng's products passed the initial review on August 12, which could expedite their market access [1] Group 3: Market Impact - Inclusion in the commercial insurance innovative drug directory would provide commercial insurance support for Beihai Kangcheng's drugs, potentially reducing the economic burden on patients and improving drug accessibility [1] Group 4: Strategic Partnerships - On August 13, Beihai Kangcheng announced a share subscription agreement with Baiyang Pharmaceutical, with Baiyang investing 100 million HKD in Beihai Kangcheng [1] - The agreement includes an exclusive commercialization service contract, allowing Baiyang's subsidiaries to promote specific Beihai Kangcheng products in mainland China, Hong Kong, and Macau [1]
北海康成再涨超19% 年内累涨逾20倍 三款产品通过商保创新药目录初审